Detalhe da pesquisa
1.
A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancer.
Invest New Drugs
; 33(2): 480-9, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25431127
2.
Composition of gastrointestinal microbiota in association with treatment response in individuals with metastatic castrate resistant prostate cancer progressing on enzalutamide and initiating treatment with anti-PD-1 (pembrolizumab).
Neoplasia
; 32: 100822, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35908379
3.
A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone.
J Immunother Cancer
; 8(2)2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32616555
4.
Gene expression profiling of whole blood: comparison of target preparation methods for accurate and reproducible microarray analysis.
BMC Genomics
; 10: 2, 2009 Jan 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-19123946
5.
Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer.
Eur J Cancer
; 81: 228-236, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28502694
6.
Androgen receptor amplification is concordant between circulating tumor cells and biopsies from men undergoing treatment for metastatic castration resistant prostate cancer.
Oncotarget
; 8(42): 71447-71455, 2017 Sep 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-29069718
7.
Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer.
Oncotarget
; 7(33): 52810-52817, 2016 Aug 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-27429197